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viral-induced encephalomyelitis and demyelination
Caroline A Blanc1, Hugh Rosen2 and Thomas E Lane3*Abstract
Background: FTY720 (fingolimod) is the first oral drug approved by the Food and Drug Administration for treatment
of patients with the relapsing-remitting form of the human demyelinating disease multiple sclerosis. Evidence suggests
that the therapeutic benefit of FTY720 occurs by preventing the egress of lymphocytes from lymph nodes thereby
inhibiting the infiltration of disease-causing lymphocytes into the central nervous system (CNS). We hypothesized that
FTY720 treatment would affect lymphocyte migration to the CNS and influence disease severity in a mouse model of
viral-induced neurologic disease.
Methods: Mice were infected intracranially with the neurotropic JHM strain of mouse hepatitis virus. Infected animals
were treated with increasing doses (1, 3 and 10 mg/kg) of FTY720 and morbidity and mortality recorded. Infiltration of
inflammatory virus-specific T cells (tetramer staining) into the CNS of FTY720-treated mice was determined using flow
cytometry. The effects of FTY720 treatment on virus-specific T cell proliferation, cytokine production and cytolytic
activity were also determined. The severity of neuroinflammation and demyelination in FTY720-treated mice was
examined by flow cytometry and histopathologically, respectively, in the spinal cords of the mice.
Results: Administration of FTY720 to JHMV-infected mice resulted in increased clinical disease severity and mortality.
These results correlated with impaired ability to control viral replication (P < 0.05) within the CNS at days 7 and 14
post-infection, which was associated with diminished accumulation of virus-specific CD4+ and CD8+ T cells (P < 0.05)
into the CNS. Reduced neuroinflammation in FTY720-treated mice correlated with increased retention of T lymphocytes
within draining cervical lymph nodes (P < 0.05). Treatment with FTY720 did not affect virus-specific T cell proliferation,
expression of IFN-γ, TNF-α or cytolytic activity. FTY720-treated mice exhibited a reduction in the severity of demyelination
associated with dampened neuroinflammation.
Conclusion: These findings indicate that FTY720 mutes effective anti-viral immune responses through impacting
migration and accumulation of virus-specific T cells within the CNS during acute viral-induced encephalomyelitis.
FTY720 treatment reduces the severity of neuroinflammatory-mediated demyelination by restricting the access of
disease-causing lymphocytes into the CNS but is not associated with viral recrudescence in this model.
Keywords: FTY720, S1P receptor, virus, central nervous system, T lymphocytes, demyelinationBackground
Multiple sclerosis (MS) is a neurodegenerative inflam-
matory disease of the central nervous system (CNS),
which leads to demyelination and progressive neurological
disability [1,2]. FTY720, also called Gilenya/fingolimod,
is an oral drug recently approved by the Food and Drug
Administration (FDA) for treatment of patients with
the relapsing-remitting form of MS [3–8]. FTY720 is an* Correspondence: tom.lane@path.utah.edu
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University of Utah School of Medicine, Salt Lake City, Utah 84112, USA
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unless otherwise stated.immunomodulatory drug that has shown to reduce both
acute relapses but also new lesion formation as well as
disability progression and brain volume loss in MS
patients [9]. The mechanisms for how FTY720 functions
are not yet defined; however, the phosphorylated active
form of FTY720 (FTY720P) is a sphingosine-1-phosphate
(S1P) receptor modulator that inhibits egress of lympho-
cytes from lymph nodes [9–11]. It is thought that this
leads to a dampening of autoreactive T cells specific for
myelin antigens infiltrating into the CNS. Importantly,
FTY720, due to its lipophilic nature, penetrates thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.jneuroinflammation.com/content/11/1/138blood–brain-barrier and readily enters the CNS paren-
chyma [9]. Furthermore, FTY720P is detected in situ,
suggesting that it may influence the biology of resident
cells of the CNS [9].
FTY720 has been shown to improve disease severity in
experimental autoimmune encephalomyelitis (EAE), an
autoimmune model of neuroinflammation and demyelin-
ation commonly used as a model for MS [12–14]. Indeed,
therapeutic administration of FTY720 in EAE models is
associated with reduced neuroinflammation and improved
motor skills [12–15]. In addition to EAE, viral models of
demyelination are also relevant tools for studying the
pathogenesis of neuroinflammatory-mediated demyelin-
ation. For example, infection of susceptible mice with the
neurotropic JHM strain of mouse hepatitis virus (JHMV)
results in an acute encephalomyelitis followed by chronic
demyelination. Like MS, components of the immune
system, such as T cells and macrophages, are important
contributors to white matter destruction [16–18]. More-
over, JHMV-infected mice undergoing chronic demyelin-
ation show similar clinical and histologic disease profiles
compared to MS patients [19–21]. As viruses are consid-
ered to be a contributing cause of MS [22–35], JHMV
infection of the CNS offers not only an excellent model
for studying the immunopathological mechanism driving
demyelination in MS patients but also can provide insight
into effects of MS therapeutics within the context of viral-
induced demyelination. We have evaluated the effects of
FTY720 on both host defense and disease progression in
JHMV-infected mice. Our findings reveal that FTY720
treatment resulted in increased mortality associated with
impaired ability to control viral replication. FTY720 did
not alter anti-viral effects of T cells, e.g. cytokine secre-
tion or cytolytic activity, but affected lymphocyte egress
from draining cervical lymph nodes and accumulation of
virus-specific T cells within the CNS. Therefore, FTY720
treatment mutes effective anti-viral immune responses
following infection with a neurotropic virus by dampening
trafficking of virus-specific T cells to the CNS. Conversely,
administration of FTY720 to JHMV-infected mice reduced
the severity of demyelination by limiting infiltration of
inflammatory T cells into the CNS.
Methods
Virus and mice
Age-matched (5 to 7 weeks) S1P1 eGFP knock-in mice
(C57BL/6 background) [36] and C57BL/6 mice were
anesthetized with an intra-peritoneal (i.p.) injection of
150 μl of a mixture of ketamine (Western Medical Supply,
Arcadia, CA, USA) and xylazine (Phoenix Pharmaceutical,
Saint Joseph, MO, USA) in Hank’s balanced salt solution.
Mice were injected intra-cranially (i.c.) with 150 plaque
forming units (PFU) of JHMV (strain V2.2-1) suspended
in 30 μl saline [37]. Clinical severity was assessed using apreviously described four-point scoring scale [16]. FTY720
(2-amino-2- [2-(4-octylphenyl) ethyl]-1,3-propanediol, hy-
drochloride) and FTY720P (2-amino-2[2-(4-octylphenyl)
ethyl]-1,3-propanediol, mono dihydrogen phosphate ester)
were purchased from Cayman Chemical Co (Ann Arbor,
MI, USA). Administration of FTY720 or the vehicle was
performed by daily i.p. injections of 100 μl starting at day
5 post-infection (p.i.). For analysis of viral titers, mice were
sacrificed at defined time points. One half of each brain
was removed as well as spinal cords. These were homoge-
nized and used in a plaque assay performed using DBT
mouse astrocytoma cell line [38]. Experiments for all ani-
mal studies were reviewed and approved by the University
of Utah and the University of California, Irvine Institutional
Animal Care and Use Committee.
Cell isolation and flow cytometry
Immunophenotyping of the cellular infiltrate present
within cervical lymph nodes, brains and spinal cords of
infected mice was accomplished by homogenizing isolated
tissue and generating a single-cell suspension for analysis
by flow cytometry as previously described [39–41]. In
brief, isolated cells were Fc blocked with anti-CD16/32
1:200. The following antibodies were used for immu-
nophenotyping: APC-conjugated rat anti-mouse B220
for B cells; APC-conjugated rat anti-mouse CD4 for
CD4+ T cells; PE-conjugated rat anti-mouse CD8 and
APC-conjugated rat anti-mouse CD8 for CD8+ T cells;
PE-conjugated rat anti-mouse interferon-gamma (IFN-γ)
for intracellular cytokine staining; PE-Cy7-conjugated rat
anti-mouse CD45, APC-conjugated rat anti-mouse CD19
and PE-conjugated rat anti-mouse CD138 for antibody
secreting cells; M133-147 tetramer-PE for virus specific
CD4+ T cells and S510-518 tetramer-PE for virus-specific
CD8+ T cells. Cell isolates for IFN-γ intracellular staining
were cultured in 200 μl RPMI-1640 supplemented with
10% fetal bovine serum, L-glutamine and penicillin-
streptomycin, and stimulated ex vivo with the immunodo-
minant CD4 epitope (M133-147) or the immunodominant
CD8 (S510-518) and Golgi stop for 6 h followed by intra-
cellular staining [42,43]. The cells were then fixed and
permeabilized by using a BD cytofix/cytoperm plus kit
and then stained for intracellular IFN-γ for 30 min at 4°C
[44]. Immunophenotyping of lymphocytes was performed
following red blood cell lysis on blood samples collected
with heparin-coated syringes by heart puncture from S1P1
eGFP knock-in mice. Cells were then Fc blocked with
anti-CD16/32 1:200 and stained with PE-conjugated rat
anti-mouse CD3. Samples were then analyzed on a BD
LSR II flow cytometer.
Proliferation assay
Splenocytes were isolated from mice at day 8 following
i.p. infection with 2.5 × 105 PFU of the DM strain of
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http://www.jneuroinflammation.com/content/11/1/138mouse hepatitis virus (MHV-DM). Enriched populations
of CD4+ and CD8+ T cells, isolated according to the
manufacturer’s instructions (CD4 and CD8 Isolation
kits, Miltenyi Biotec, Auburn, CA, USA), were labeled
with the fluorescent dye, carboxyfluorescein diacetate
succinimidyl ester (CFSE) (Life Technologies, Grand
Island, NY, USA), at 2.5 μM final concentration. Then
1 × 106 total cells per well were incubated with FTY720P
100 nM or vehicle and stimulated with 5 μM final peptide
concentration of CD4+ T cell immunodominant epitope
M133-147, CD8+ T cell immunodominant epitope S510-
518, or non-specific OVA control, and cultured for
72 h at 37°C, 5% CO2 in complete media. Cells were
then washed and the Fc receptor blocked with 1 × PBS
containing 1% BSA and a 1:200 dilution of rat anti-mouse
CD16/32 antibody (Pharmingen, San Jose, CA, USA).
Next, cells were stained for surface antigens using APC-
conjugated rat anti-mouse CD4 and CD8 (Pharmingen,
San Jose, CA, USA), according to the viral peptide stimu-
lation condition, for 45 min at 4°C. Cells were analyzed
and the data assessed as described above.
Cytotoxic T lymphocyte assay
Spleen-derived CD8+ T cells were analyzed for lytic activity
at day 8 following i.p. infection of C57BL/6 mice withA
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Figure 1 FTY720 treatment increases clinical disease severity, mortali
mice C57BL/6 were infected i.c. with JHMV (150 PFU) and treated daily begin
n = 10 per group) or vehicle control by i.p. injection. Infected mice showed in
10 mg/ml (*P < 0.05) having the greatest effect compared to vehicle-treated c
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shaded area) results in a dose-dependent increase in mortality compared
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indicate averages. CNS viral titers represent two independent experiments. *P2.5 × 105 PFU of MHV-DM. A CD8+ T cell-enriched
population of cells was obtained via negative selection
through use of a magnetically labeled antibody specific
for the CD8 antigen followed by passage over a magnetic
column (Miltenyi Biotec, Auburn, CA, USA) [45]. The
numbers of S510-518-specific CD8+ T cells were deter-
mined by tetramer staining and these cells were used as
the effector population. RMA-S cells, a murine lymphoma
cell line that presents viral peptides to cytotoxic T lym-
phocytes (CTL), were cultured at a density of 10,000
per well in flat-bottomed 96-well format tissue culture
plate (Corning Life Sciences, Tewksbury, MA, USA) and
pulsed overnight with 5 μM of the immunodominant CD8
peptide specific for MHV spike (S) glycoprotein, spanning
amino acids 510 to 518 (S510-518, Bio-Synthesis,
Lewisville, TX, USA). CD8 T-cells, exposed to either
FTY720P (100 nM) or vehicle alone, were then plated
with RMA-S cells at effector-to-target (E:T) ratios ranging
from 20:1 to 2.5:1. Co-cultures were incubated for 4 h
at 37°C in 5% CO2 at a final volume of 200 μl per well.
The amounts of lactate dehydrogenase (LDH) released
from lysed cells were determined using a CytoTox 96
Non-Radioactive Cytotoxicity Assay (Promega, Madison,
WI, USA). The percentage of CTL-mediated lysis was
determined as specified by the manufacturer’s protocols.D
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Spleen-derived CD4+ and CD8+ T cells from MHV-DM
infected mice [39] were analyzed for cytokine secretion.
CD4+ and CD8+ T cells were isolated as described above
using an isolation kit according to the manufacturer’s
instructions (Miltenyi Biotec, Auburn, CA, USA). Then
1 × 106 T cells per well on a round bottom 96-well plate
were incubated for 48 h at 37°C in 5% CO2 in the presence
of FTY720P 100 nM or vehicle. Supernatants were then
collected and an ELISA was performed for the following
cytokines: IFN-γ and tumor necrosis factor alpha (TNF-α).
Samples were run in triplicate in accordance with the manu-
facturer’s directions (R&D Systems, Minneapolis, MN, USA).0 102 103 104 105
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Clinical severity was assessed using a previously described
four-point scoring scale [16]. Spinal cords were isolated
at defined time points and fixed overnight with 4%
paraformaldehyde at 4°C. Spinal cords were separated
into 12 coronal sections, cryoprotected in 20% sucrose
and embedded in optimum cutting temperature (O.C.T)
formulation (VWR, Radnor, PA, USA) [46]. Next 8-μm-
thick coronal sections were cut and sections were stained
with luxol fast blue (LFB). Areas of total white matter and
demyelinated white matter were determined with Image J
Software. Demyelination was scored as a percentage of total
demyelination along the entire length of the spinal cord.Me
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http://www.jneuroinflammation.com/content/11/1/138An H&E stain was performed to determine the extent of
inflammation. Spinal cord sections were scored using a
four-point scale to assess neuroinflammation [16].
Results
FTY720 treatment of JHMV-infected mice increases clinical
disease severity and impairs control of viral replication
S1P1 eGFP knock-in mice C57BL/6 mice [36] were infected
i.c. with JHMV (150 PFU) and subsequently treated with
increasing concentrations (1, 3 or 10 mg/kg) of FTY720 via
i.p. injection administered daily starting at day 5 p.i. Mice
were scored daily until day 21 p.i. FTY720 treatment
resulted in increased severity of clinical disease with the
greatest effects occurring at 3 mg/kg and 10 mg/kg doses
(P < 0.05) compared to vehicle-treated mice (Figure 1A).
In accordance with clinical data, FTY720-treated mice
exhibited increased mortality in a dose-dependent manner
(Figure 1B). By day 21 p.i., <30% of mice treated with
10 mg/kg FTY720 survived while mice treated with either
3 mg/kg or 1 mg/kg exhibited 40% and approximately
60% survival, respectively (Figure 1B). Based on the mor-
bidity and mortality data, 3 mg/kg FTY720 was used for
subsequent in vivo studies. FTY720 treatment resulted inCD
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compared to vehicle-treated control mice (Figure 1C,D).
However, at later times p.i. the majority of mice treated
with FTY720 had reduced viral titers below the level of
detection (approximately 100 PFU/g) within the brain and
spinal cord (Figure 1C,D). These findings indicated that
the increase in mortality following administration of
FTY720 correlated with impaired ability to control viral
replication within the CNS and argues that either traf-
ficking of virus-specific lymphocytes is impaired and/or
anti-viral effector functions are negatively affected.
T cell anti-viral effector function and FTY720 treatment
T cell responses, including proliferation, secretion of
IFN-γ and CTL activity, are critical in controlling JHMV
replication within the CNS [47–53]. FTY720P treatment
(100 nM) had no appreciable effect on dampening prolif-
eration of either CD8+ T cells specific for the immunodo-
minant epitope for the spike (S) glycoprotein spanning
amino acid residues 510–518 (S510-518) [42] or CD4+ T
cells recognizing the matrix (M) glycoprotein peptide 133–
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pulsed with either M133-147 or S510-518 peptides and
treated with FTY720P (100 nM) to determine if cytokine
secretion was affected. FTY720 treatment did not affect
secretion of either IFN-γ or TNF-α compared to vehicle-
treated cultures (Figure 2C). Finally, FTY720 treatment of
CD8+ T cells did not affect lytic activity compared to con-
trols (Figure 2D). These findings argue that FTY720 treat-
ment does not dampen anti-viral T cell effector functions.A
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http://www.jneuroinflammation.com/content/11/1/138not affected at days 14 and 21 p.i (Figure 3C,D). Further,
FTY720 treatment did not affect CD8+ T cell infiltration
into the CNS at days 7, 14 and 21 p.i. (Figure 3C,E).
Infiltration of virus-specific CD4+ and CD8+ T cells,
as determined by intracellular IFN-γ staining in response
to treatment with immunodominant CD4+ and CD8+
viral epitopes [42,43], was diminished at days 7 (P < 0.01)
and 14 (P < 0.05) following FTY720 treatment in compari-
son to vehicle-treated mice (Figure 4A,B). By day 21 p.i.,
infiltration of virus-specific CD4+ T cells, but not
virus-specific CD8+ T cells, was also reduced (P < 0.05)
in FTY720-treated mice compared to control animals
(Figure 4B). Infiltration of antibody secreting cells (ASCs)
(CD45−CD19low CD138+) into the CNS of JHMV-infected
mice was not reduced at either days 7, 14 or 21 p.i. fol-
lowing FTY720 treatment compared to control mice
(Figure 4C,D). These findings indicate that administration
of FTY720 negatively impacts recruitment of T lympho-
cytes into the CNS in response to JHMV infection.
FTY720 restricts lymphocyte egress from draining cervical
lymph nodes
As an S1P1 functional antagonist, FTY720 disrupts the S1P
gradient in lymph nodes thereby trapping lymphocytes
[4,5]. To establish if this occurs during ongoing neuro-
inflammation in response to infection with neurotropic
JHMV, draining cervical lymph nodes (dCLNs) wereA
D
B
Figure 5 Increased lymphocyte retention in dCLNs following FTY720
with JHMV (150 PFU) and treated daily with FTY720 (3 mg/kg) beginning o
size, weight and immunophenotype lymphocyte population by flow cytom
obtained from FTY720-treated mice compared to vehicle control-treated m
FTY720 treatment compared to vehicle (P < 0.05). Treatment with FTY720 re
and CD8+ T cells (E) at defined times p.i. Data in panels B to E represent a
with a minimum of four mice/group. *P <0.05, *** P <0.001. cLN, cervical lyexamined at defined times p.i. following treatment with
FTY720. Administration of FTY720 revealed an increase
in size and weight of dCLNs in FTY720-treated mice
compared to control mice at day 7 p.i. (Figure 5A,B).
Immunophenotyping lymphocytes in dCLNs by flow cy-
tometry revealed an increased frequency of B220+ B cells
(Figure 5C), CD4+ T cells (Figure 5D) and CD8+ T cells
(Figure 5E) in mice treated with FTY720 compared to
controls, indicating increased retention of lymphocytes in
lymphatic tissue in response to S1P antagonism.
FTY720 diminishes the severity of demyelination in
JHMV-infected mice
To investigate the potential effect of FTY720 on spinal
cord neuroinflammation and demyelination in JHMV-
infected mice, an evaluation of the severity of white
matter damage was performed at day 21 p.i. Spinal cord
inflammation was reduced (P < 0.05) within spinal cords
at day 21 p.i. as assessed by H&E staining (Figure 6A,B).
Moreover, LFB staining revealed a significant (P < 0.05)
reduction in demyelination in response to FTY720
treatment compared to control mice (Figure 6A,B). Immu-
nophenotyping of infiltrating lymphocytes in the spinal
cord day 21 p.i. revealed a decrease in CD8+ T cell as well
as CD4+ T cell percentages (P <0.05) in FTY720-treated
mice compared to vehicle-treated mice (Figure 6C,D). This
suggests that reduction in the severity of demyelinationC
E
treatment of JHMV-infected mice. S1P1 eGFP mice were i.c. infected
n day 5 p.i. On days 7, 14 and 21 p.i., dCLNs were isolated to examine
etry. (A) Representative image depicting the increase in size of dCLNs
ice at day 7 p.i. (B) Average weight of dCLNs increased in response to
sulted in increased retention of B220+ B cells (C), CD4+ T cells (D)
verage ± SEM obtained from two or three independent experiments
mph node. dCLN, draining cervical lymph node.
AB
C
D
Figure 6 (See legend on next page.)
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Figure 6 FTY720 treatment reduces the severity of JHMV-induced demyelination. (A) Representative LFB and H&E-stained spinal cord images
showing an overall reduction in the severity of inflammation and demyelination within white matter tracts (dashed lines) in JHMV-infected eGFP S1P1
mice treated with FTY720 (3 mg/kg) compared to vehicle control-treated mice at day 21 p.i. (B) FTY720 treatment results in reduced neuroinflammation
(P< 0.05) and demyelination (P< 0.05) compared to mice treated with the vehicle control. Flow analysis of spinal cords demonstrates reduced entry of
both CD8+ (C) and CD4+ T cells (D), while infiltration of virus-specific T cells was not affected. Data in panel B represent two independent experiments
with a minimum of ten mice/group. Data in panels C and D are presented as average + SEM and represent two independent experiments with a
minimum of five mice/group. *P <0.05. The scale bar in panel A represents 200 μm. SSC, side scatter.
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infiltration of inflammatory cells into the spinal cord.
Discussion
FTY720/fingolimod was the first oral treatment approved
by the FDA for relapsing forms of MS [10,54,55].
Numerous clinical trials highlighted FTY720 efficacy
as demonstrated by benefits for relapses and magnetic
resonance imaging (MRI) lesions [9]. In addition, disability
progression was impacted and there was a reduction in
brain volume loss in MS patients in response to treatment
[56,57]. Although the mechanisms by which FTY720
exerts a protective effect are not defined, it is generally
accepted that the main mode of action is via an immuno-
modulatory effect by restricting lymphocyte circulation
from lymph nodes to the CNS. Dampened accumulation
of activated lymphocytes in the CNS in response to
FTY720 treatment most likely accounts for reduced MRI
lesion activity and this is supported in preclinical animal
studies using EAE [14,15,58]. Whether the reduction in
brain volume loss is also dependent upon reduced neuro-
inflammation or a direct neuroprotective effect has not
been determined. Recent evidence argues that FTY720
exerts a neuroprotective effect as animals in which the
receptor S1P1 is selectively ablated on astrocytes are
resistant to the protective effects of FTY720 treatment
following induction of EAE, although S1P1 remains
expressed on circulating lymphocytes [12,59]. However,
more recent studies by Cahalan et al. indicate that S1P1
antagonism reverses EAE without acting on S1P1 expressed
within the CNS, supporting the notion that restricting
lymphocyte egress from lymphatic tissue is sufficient to
diminish disease severity [60]. Moreover, the maintenance
of egress inhibition is not required for efficacy in EAE if
brain levels of agonist are maintained in the steady state.
Full efficacy is achieved with inhibition of egress for only
30% of the 24-h dosing interval with complete recovery of
circulating lymphocytes. Direct effects within the CNS were
demonstrated for neurons, astrocytes and the blood–brain-
barrier, and on the inhibition of migration of lymphocytes
from perivascular cuffs into the parenchyma [61].
We chose a model of viral-induced neurologic disease
to determine if FTY720 treatment affects host defense and
disease progression. Our rationale for using the JHMV
model of acute encephalomyelitis and demyelination toassess the therapeutic benefit of FTY720 is based on the
fact that the overwhelming majority of preclinical animal
models examining the mode of action for FTY720 is
derived from EAE, yet how this drug affects models of
viral-induced CNS disease are not well characterized.
In addition, viral infections have long been thought to
have a role in either initiating or contributing to relapse
in MS patients [28–34,62]. How treatment with FTY720
influences outcomes in response to viral infection is high-
lighted by recent clinical studies detailing the emergence
of herpes zoster and associated neurologic complications
in MS patients during FTY720 treatment [63,64]. These
findings suggest immunosuppression may arise in re-
sponse to FTY720 treatment resulting in re-emergence of
persistent viruses. However, administration of FTY720 to
mice infected with lymphocytic choriomeningitis did not
ameliorate persistence, indicating that the outcome may
be dictated, in part, by the virus and sites of infection [65].
Related to these observations are studies demonstrating
that treatment with FTY720 or other S1P1 agonists dra-
matically affects cytokine production and disease outcome
in mice infected with influenza virus, indicating the
immunomodulatory effects of such treatment [66]. With
regards to viral models of demyelination, Pachner and col-
leagues [67] demonstrated that administration of FTY720
had no effect on clinical disease progression or viral load
within the CNS using Theiler’s murine encephalomyelitis
virus model of demyelination. These findings are in con-
trast with findings using EAE, in which FTY720 treatment
reduced clinical disease severity accompanied by limited
infiltration of immune cells into the CNS [13–15,68,69].
Our findings show that FTY720 treatment for JHMV-
infected mice increased clinical disease severity as well
as mortality. Importantly, these findings correlate with
impaired ability to control viral replication within the
CNS. The muted host defense resulting from S1P receptor
antagonism was not the result of dampened anti-viral
T cell effector responses, e.g. proliferation, cytokine
secretion or CTL activity, but rather an inability of
lymphocytes to migrate and accumulate within the CNS
effectively. Indeed, administration of FTY720 increased
retention of T and B lymphocytes within the dCLNs,
consistent with earlier reports that blocking S1P receptors
disrupts lymphocyte egress from secondary lymphatic
tissue [70,71]. Although viral titers were elevated within
Blanc et al. Journal of Neuroinflammation 2014, 11:138 Page 10 of 12
http://www.jneuroinflammation.com/content/11/1/138the CNS of FTY720-treated mice, surviving mice were
able to reduce the amount of virus below the level of
detection and this lasted to day 28 p.i., arguing that
viral recrudescence does not occur in this model.
Administration of FTY720 either prophylactically or
therapeutically in models of EAE results in reduced
lymphocyte penetration into the CNS, which is associ-
ated with a reduction in the severity of demyelination
[14,15,58]. Similarly, our results show that the effects of
FTY720 treatment on CNS inflammation in JHMV-
infected mice correlates with a reduction in the severity
of spinal cord demyelination. Examination of the posterior
funiculus and lateral white matter columns of FTY720-
treated mice compared to controls showed an overall
reduction in lesion size, demonstrating that in addition to
reducing myelin damage in EAE, FTY720 is also effective
in limiting the spread of demyelination in a viral model
of MS. FTY720 has also been shown to prevent axonal
damage in EAE [58]. FTY720 in combination with other
drugs in EAE or cerebellar slice cultures has been shown
to augment remyelination, supporting a regenerative
potential [72,73]. These findings support that FTY720
may act directly upon resident cells of the CNS promoting
protection and repair. This is supported by elegant studies
from Chun and colleagues [12] that showed attenuation in
EAE and a loss of FTY720 efficacy in conditional null
mouse mutants lacking S1P1 in astrocytes. These findings
highlight that FTY720-mediated protection in EAE occurs
via a nonimmunological mechanism and suggest that
targeting S1P signaling within the CNS may be relevant
for recovery for both EAE and MS patients. Whether
extensive axonal sparing and/or remyelination occurs
following FTY720 administration to JHMV-infected mice
is not known at this time and is an area of ongoing work.
Conclusions
In this study we demonstrate that FTY720 mutes effective
anti-viral immune responses by preventing migration and
accumulation of virus-specific T cells within the CNS
during acute viral-induced encephalomyelitis. FTY720
treatment reduces the severity of neuroinflammatory-
mediated demyelination by limiting T cell egress from
lymph nodes thereby reducing lymphocyte infiltration
into the CNS. FTY720 did not alter anti-viral effects of
T cells, e.g. cytokine secretion or cytolytic activity.
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